SGLT2 inhibitors, GLP-1 RAs, and DPP4 inhibitors and the risk of hypomagnesemia in type 2 diabetes: A target trial emulation - PubMed
5 days ago
- #diabetes
- #drug-comparison
- #hypomagnesemia
- Study compares SGLT2 inhibitors, GLP-1 RAs, and DPP4 inhibitors for hypomagnesemia risk in type 2 diabetes.
- SGLT2 inhibitors showed lower hypomagnesemia risk vs. DPP4 inhibitors (HR: 0.80) and GLP-1 RAs (HR: 0.92).
- GLP-1 RAs also had lower hypomagnesemia risk compared to DPP4 inhibitors (HR: 0.89).
- Findings suggest SGLT2 inhibitors and GLP-1 RAs may be better for patients at risk of hypomagnesemia.
- Study limitations include potential residual confounding from retrospective observational design.